

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

Cinvanti (aprepitant) injection

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Cinvanti (aprepitant) injection	May be subject to quantity limit

APPROVAL CRITERIA

Requests for Cinvanti (aprepitant) injection may be approved if the following criteria are met:

- I. Individual is using to prevent acute and delayed nausea and vomiting associated with initial and repeat courses of highly and moderately emetogenic cancer chemotherapy;
- AND**
- II. Individual is using in combination other antiemetic agents (serotonin receptor antagonist [5HT-3] and dexamethasone) (NCCN 1).

Requests for Cinvanti (aprepitant) injection may **not** be approved for the following:

- I. Treatment of established nausea and vomiting; **OR**
- II. Concomitant use with pimozide (Orap).

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

Key References:

PAGE 1 of 2 03/12/2019
New Program Date 03/12/2019

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

CRX-ALL-0354-19

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2018.
URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website.
<http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: October 2, 2018.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2018; Updated periodically.
5. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Antiemesis. Version 3.2018. Available from https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf. Accessed September 27, 2018.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

CRX-ALL-0354-19